The effects of danazol on calcium homeostasis in normal postmenopausal women was examined in a 14day study utilizing a dosage of 800 mg per day. Danazol caused significant falls in plasma ionized calcium and in the fasting urinary calcium/creatinine ratio, indicating inhibition of bone resorption. Retention of phosphate was also observed as expected with this anabolic agent. The plasma total alkaline phosphatase was also depressed by the drug, which had no effect on hepatocellular function as measured by plasma AST. Certain effects induced by treatment with danazol were still apparent two weeks after cessation of treatment. The drug was well tolerated and androgenic side effects were not seen. It is suggested that the minimal dose regimen of danazol which exerts a calcium-sharing effect should be identified, and that this regimen should be considered for use in a prospective study of the effects ofdanazol on bone mineral content in the postmenopause.
Introduction
The determinants of human bone mineral content (BMC) are complex and involve genetic, nutritional, and endocrine factors. Although the latter are probably permissive rather than causal in altering BMC 1, their optimal manipulation for bone conservation in the postmenopause has been investigated intensively in recent years, one such approach being through the use of exogenous sex steroids. Bone resorption may be inhibited -by an oestrogen alone or in combination with certain progestogens, but the use of such preparations may be attended by unacceptable hazards or side effects". Recently, evidence has been accumulating that certain non-oestrogenic sex steroids may exert a positive effect on bone conservation in the postmenopause'. Norethisterone has recently been shown to inhibit bone resorption" but its long-term efficacy in the conservation of BMC has yet to be tested by clinical trial. The use of anabolic steroids such as stanozolol has also been studied experimentally', but a high incidence of biochemical side effects has inhibited their more general application.
Danazol, an isoxazol derivative of testosterone, is a weak androgen. It is anabolic, but has no oestrogenic or progestogenic activity" and is widely used in clinical practice to induce secondary amenorrhoea in cases of endometriosis. Its chemical similarity to stanozolol which is known to preserve total body calcium7, together with its relative freedom from adverse effects, prompted us to investigate its effect on calcium homeostasis in normal postmenopausal women.
Methods
Fourteen healthy volunteers aged between 47 and 62 years were recruited. All were within 10 years of a natural menopause and none either suffered from any condition, or had recently been exposed to any agent known to affect mineral metabolism. Each patient ingested danazolBOO mg daily for 14days. One patient developed a skin eruption of uncertain origin and was withdrawn. No androgenic effects were observed. The studies noted below were performed prior to treatment, on the 14th treatment day, and on the 14th post-treatment day.
Plasma and urine samples were taken in each case after an overnight fast, the urine specimen being collected 2 hours after discard of the first morning specimen. Plasma total calcium, creatinine, phosphate, alkaline phosphatase and aspartate aminotransferase (AST) were measured on a Technicon SMAC autoanalyser. Urine calcium, creatinine, sodium and phosphate were also measured in a SMAC autoanalyser after appropriate specimen dilution. Plasma ionized calcium was measured using a Nova 2 ionized calcium analyser. Tubular maxima for reabsorption of calcium and phosphate were calculated as described by Marshall", Both post-treatment sets of data from each patient were compared to the pretreatment analysis using paired t tests. In the case of urinary calcium/ creatinine ratios only, non-parametric testing was used to confirm the significances reported with parametric testing in view of the large standard deviations encountered.
Results
Danazol treatment for 14 days resulted in a significant fall in plasma ionized calcium and in the urinary excretion of calcium and phosphate as judged by the fasting calcium/creatinine and phosphate creatinine ratios. There was also a significant depression of plasma alkaline phosphatase and an increase in plasma creatinine. No significant changes were observed in plasma total calcium or phosphate or in the tubular maxima for reabsorption of either mineral. Plasma AST was similarly unchanged.
By the 14th post-treatment day, plasma ionized calcium had recovered to show a significant rise over basal levels. The urinary calcium/creatinine ratio remained depressed but not significantly so, and this ratio was not influenced by the urinary sodium excretion which was unchanged throughout this study. Plasma alkaline phosphatase did remain significantly depressed and plasma AST had become so. Plasma creatinine had normalized and both plasma total calcium and phosphate had shown no change 0141-0768/87 011681-02/$02.00/0 Cll987 The Royal Society of Medicine Significance (compared to pre-treatment): • P < 0.05, • P < 0.01, • P < 0.0005 throughout the study. The tubular maximum for reabsorption of calcium was similarly unchanged, while that for phosphate was significantly lowered only on the 14th post-treatment day. The results are summarized in Table 1 .
Discussion
The results indicate that danazol in a dose of BOO mg a day appears to modify mineral metabolism towards conservation of calcium and phosphate in the sample of normal postmenopausal women studied. A reduction in bone resorption in these women is suggested by the significant falls observed after 14 days' treatment in the plasma ionized calcium and in the fasting urinary calcium/creatinine ratio. Both these effects are observed in normal postmenopausal women given oestrogen" and are thought to reflect a diminution in bone turnover with less calcium being released into the circulation. Danazol also caused a highly significant and sustained fall in plasma alkaline phosphatase, an effect not seen with oestrogen, and similar to that observed in postmenopausal women given norethisterone" and stanozolol". The rise observed in plasma creatinine is also seen with stanozolol and probably reflects the known anabolic effects of such agents. The absence of any observed alteration of TOle. or T mp after 14 days treatment suggests that the effects of danazol on calcium and phosphate urinary excretion are not mediated via parathyroid hormone action on the kidney.
The only significant effect of danazol which was sustained until the 14th post-treatment day was the reduction in plasma alkaline phosphatase. It remains to be seen if this reduction in total alkaline phosphatase masks a rise in the bone-specific isoenzyme, as has been observed with stanozolol", such a rise being taken to indicate enhanced bone formation. The reduction in the calcium/creatinine ratio, which had been significant on the 14th treatment day, was sustained until the 14th post-treatment day but just failed to achieve significance at this point (P= 0.056). With regard to phosphate, the reduced tubular resorption and increased urine excretion present on the 14th post-treatment day are taken to indicate disposal of phosphate retained anabolically during treatment. The sustained normality of AST indicates that hepatotoxicity does not appear to be a problem with the dose regimen and timescale employed.
Further studies are in hand to determine the minimum dose of danazol which will exert a significant inhibition of bone resorption measured biochemi-cally, and to confirm that such inhibition is reflected biophysically through histomorphometric evidence of reduced resorption and/or enhanced formation in bone biopsy specimens.
Osteoporosis and related fractures impose a major financial consequence on the NHS, and its prevention rather than treatment must remain the ultimate therapeutic goal. Adequate dietary calcium and physical exercise will always remain important factors in preventing the condition1, but these may well need to be supplemented by an agent which permissively alters the hormonal status of the patient. Although weak, danazol is an androgen and it remains to be seen if a reduced dose regimen can be found which, while sufficient to prevent excess calcium loss, will also be acceptable to patients and avoid significant androgenic and other side effects in the long term. This latter point would require to be established in a prospective clinical trial of the efficacy of danazol in the preservation of bone mineral content in normal postmenopausal women.
